Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/androprostamine-a-a-unique-antiprostate-cancer-agent-zN1KnT8Smq
References (38)
-
Yingming Li, T. Hwang, L. Oseth, Adam Hauge, R. Vessella, S. Schmechel, B. Hirsch, K. Beckman, K. Silverstein, S. Dehm (2011)
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionOncogene, 31
-
Li Ni, Chun-song Yang, D. Gioeli, H. Frierson, D. Toft, B. Paschal (2010)
FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer CellsMolecular and Cellular Biology, 30
-
K. Minamiguchi, M. Kawada, T. Someno, M. Ishizuka (2003)
Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness.Biochemical and biophysical research communications, 306 3
-
S. Korenchuk, J. Lehr, Lisa McLean, Y. Lee, S. Whitney, R. Vessella, D. Lin, K. Pienta (2001)
VCaP, a cell-based model system of human prostate cancer.In vivo, 15 2
-
Hikaru Abe, Y. Yamazaki, Chiharu Sakashita, I. Momose, Takumi Watanabe, M. Shibasaki (2016)
Synthesis of Androprostamine A and Resormycin.Chemical & pharmaceutical bulletin, 64 7
-
T. Yamori, Akio Matsunaga, Shigeo Sato, K. Yamazaki, A. Komi, K. Ishizu, Izumi Mita, H. Edatsugi, Y. Matsuba, K. Takezawa, O. Nakanishi, H. Kohno, Y. Nakajima, H. Komatsu, Toshio Andoh, T. Tsuruo (1999)
Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.Cancer research, 59 16
-
E. Mostaghel, B. Marck, S. Plymate, R. Vessella, S. Balk, A. Matsumoto, P. Nelson, B. Montgomery (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice VariantsClinical Cancer Research, 17
-
Wennuan Liu, Chunmei Xie, Yi Zhu, Tao Li, Jishan Sun, Y. Cheng, C. Ewing, Susan Dalrymple, A. Turner, Jielin Sun, J. Isaacs, B. Chang, S. Zheng, W. Isaacs, Jianfeng Xu (2008)
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.Neoplasia, 10 8
-
A. Migliaccio, G. Castoria, M. Domenico, A. Falco, A. Bilancio, M. Lombardi, M. Barone, Donatella Ametrano, M. Zannini, C. Abbondanza, F. Auricchio (2000)
Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferationThe EMBO Journal, 19
-
R. Hu, T. Dunn, Shuanzeng Wei, S. Isharwal, R. Veltri, E. Humphreys, Misop Han, A. Partin, R. Vessella, W. Isaacs, G. Bova, Jun Luo (2009)
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.Cancer research, 69 1
-
N. Nadiminty, R. Tummala, Chengfei Liu, Joy Yang, W. Lou, C. Evans, A. Gao (2013)
NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its VariantsMolecular Cancer Therapeutics, 12
-
Zhiyong Guo, Xi Yang, F. Sun, R. Jiang, Douglas Linn, Hege Chen, Hegang Chen, X. Kong, J. Melamed, C. Tepper, H. Kung, A. Brodie, J. Edwards, Y. Qiu (2009)
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.Cancer research, 69 6
-
P. Rennie, C. Nelson (1998)
Epigenetic Mechanisms for Progression of Prostate CancerCancer and Metastasis Reviews, 17
-
James Joseph, Nhin Lu, J. Qian, J. Sensintaffar, G. Shao, D. Brigham, Michael Moon, E. Maneval, I. Chen, B. Darimont, J. Hager (2013)
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.Cancer discovery, 3 9
-
P. Lonergan, D. Tindall (2011)
Androgen receptor signaling in prostate cancer development and progressionJournal of Carcinogenesis, 10
-
Yasser Rehman, J. Rosenberg (2012)
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancerDrug Design, Development and Therapy, 6
-
Y. Yamazaki, T. Someno, M. Igarashi, N. Kinoshita, Masaki Hatano, M. Kawada, I. Momose, A. Nomoto (2014)
Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8The Journal of Antibiotics, 68
-
I. Tannock, R. Wit, W. Berry, J. Horti, A. Płużańska, K. Chi, S. Oudard, C. Théodore, N. James, I. Turesson, M. Rosenthal, M. Eisenberger (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.The New England journal of medicine, 351 15
-
A. Jemal, R. Siegel, Elizabeth Ward, Y. Hao, Jiaquan Xu, M. Thun (2009)
Cancer Statistics, 2009CA: A Cancer Journal for Clinicians, 59
-
Yingming Li, S. Chan, L. Brand, T. Hwang, K. Silverstein, S. Dehm (2013)
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.Cancer research, 73 2
-
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
-
A. Zamagni, M. Cortesi, M. Zanoni, A. Tesei (2019)
Non-nuclear AR Signaling in Prostate CancerFrontiers in Chemistry, 7
-
Jelani Zarif, C. Miranti (2016)
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.Cellular signalling, 28 5
-
E. Falkenstein, H. Tillmann, M. Christ, M. Feuring, M. Wehling (2000)
Multiple actions of steroid hormones--a focus on rapid, nongenomic effects.Pharmacological reviews, 52 4
-
P. Koivisto, J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, J. Isola, J. Trapman, K. Cleutjens, A. Noordzij, T. Visakorpi, O. Kallioniemi (1997)
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.Cancer research, 57 2
-
B. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Yonghong Xiao, B. Carver, V. Arora, Poorvi Kaushik, E. Cerami, B. Reva, Yevgeniy Antipin, N. Mitsiades, Thomas Landers, Igor Dolgalev, John Major, Manda Wilson, N. Socci, A. Lash, A. Heguy, J. Eastham, H. Scher, V. Reuter, P. Scardino, C. Sander, C. Sawyers, W. Gerald (2010)
Integrative genomic profiling of human prostate cancer.Cancer cell, 18 1
-
C. Chen, D. Welsbie, C. Tran, S. Baek, Randolph Chen, R. Vessella, M. Rosenfeld, C. Sawyers (2004)
Molecular determinants of resistance to antiandrogen therapyNature Medicine, 10
-
Shihua Sun, C. Sprenger, R. Vessella, K. Haugk, Kathryn Soriano, E. Mostaghel, S. Page, Ilsa Coleman, H. Nguyen, Huiying Sun, P. Nelson, S. Plymate (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.The Journal of clinical investigation, 120 8
-
C. Tran, Samedy Ouk, N. Clegg, Yu Chen, Philip Watson, V. Arora, John Wongvipat, P. Smith-Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, D. Welsbie, C. Chen, C. Higano, T. Beer, D. Hung, H. Scher, M. Jung, C. Sawyers (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 324
-
Qianben Wang, J. Carroll, Myles Brown (2005)
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.Molecular cell, 19 5
-
S. Dehm, D. Tindall (2011)
Alternatively spliced androgen receptor variants.Endocrine-related cancer, 18 5
-
J. Leung, M. Sadar (2017)
Non-Genomic Actions of the Androgen Receptor in Prostate CancerFrontiers in Endocrinology, 8
-
H. Peterziel, S. Mink, Annette Schonert, M. Becker, H. Klocker, A. Cato (1999)
Rapid signalling by androgen receptor in prostate cancer cellsOncogene, 18
-
L. Scott (2018)
Enzalutamide: A Review in Castration-Resistant Prostate CancerDrugs, 78
-
A. Jemal, R. Siegel, Jiaquan Xu, Elizabeth Ward (2010)
Cancer Statistics, 2010CA: A Cancer Journal for Clinicians, 60
-
S. Henshall, D. Quinn, C. Lee, D. Head, D. Golovsky, P. Brenner, W. Delprado, P. Stricker, J. Grygiel, R. Sutherland (2001)
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.Cancer research, 61 2
-
L. Tanoue (2010)
Cancer Statistics, 2009Yearbook of Pulmonary Disease, 2010
-
Jelani Zarif, L. Lamb, V. Schulz, Eric Nollet, C. Miranti (2015)
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptaseOncotarget, 6
- Publisher
- Springer Journals
- Copyright
- Copyright © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2021. corrected publication 2021
- ISSN
- 0021-8820
- eISSN
- 1881-1469
- DOI
- 10.1038/s41429-021-00449-8
- Publisher site
- See Article on Publisher Site
Abstract
The androgen receptor (AR) is an important therapeutic target for all clinical states of prostate cancer. We screened cultured broths of microorganisms for their ability to suppress androgen-dependent growth of human prostate cancer LNCaP and VCaP cells without cytotoxicity. We have already identified androprostamine A (APA) from a Streptomyces culture broth as a functional inhibitor of AR. APA repressed R1881 (the synthetic androgen methyltrienolone)-induced androgen-regulated gene expression and dramatically inhibited R1881-induced prostate-specific antigen levels. However, APA did not act as an AR antagonist and did not inhibit AR transcriptional activity. Moreover, AS2405, an APA derivative, significantly inhibited the growth of VCaP cells in SCID mice upon oral administration.
Journal
The Journal of Antibiotics – Springer Journals
Published: Oct 1, 2021